Holen Sie sich die Stockscreener-App
13.68
2.83%
0.3735
Schlusskurs vom Vortag:
$13.31
Offen:
$13.24
24-Stunden-Volumen:
1.77M
Relative Volume:
0.37
Marktkapitalisierung:
$1.63B
Einnahmen:
$67.67M
Nettoeinkommen (Verlust:
$-412.69M
KGV:
-3.5759
EPS:
-3.8266
Netto-Cashflow:
$-395.87M
1W Leistung:
+9.98%
1M Leistung:
+2.91%
6M Leistung:
+11.09%
1J Leistung:
+88.78%
1-Tages-Spanne:
$13.11
$13.80
1-Wochen-Bereich:
$12.62
$14.33
52-Wochen-Spanne:
$6.83
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Firmenname
Intellia Therapeutics Inc
Sektor
Branche
Telefon
857-285-6200
Adresse
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
13.69 | 1.58B | 67.67M | -412.69M | -395.87M | -3.8266 |
VRTX
Vertex Pharmaceuticals Inc
|
425.31 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
718.96 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
809.17 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.17 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
316.07 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-11-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-11-11 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-11-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-10-28 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-02-28 | Herabstufung | Goldman | Neutral → Sell |
| 2025-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-04-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-03-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Sell |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-06-16 | Eingeleitet | BofA Securities | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-02-18 | Eingeleitet | William Blair | Outperform |
| 2022-02-07 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Eingeleitet | Cowen | Outperform |
| 2022-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-05 | Eingeleitet | Guggenheim | Buy |
| 2021-09-24 | Eingeleitet | Stifel | Buy |
| 2021-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-07 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-22 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Eingeleitet | Truist | Buy |
| 2020-10-14 | Eingeleitet | Wells Fargo | Overweight |
| 2020-09-18 | Eingeleitet | Goldman | Buy |
| 2020-02-28 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-11-01 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-10 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-11-02 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-10-29 | Eingeleitet | Credit Suisse | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Mkt Perform |
| 2018-05-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2017-11-01 | Bestätigt | Jefferies | Buy |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-05 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Motley Fool
Intellia Therapeutics Stock Is Down Nearly 95% From Its Record Highs but Cathie Wood Keeps Buying - Barchart
Intellia Therapeutics Announces Investor Conference Participation on May 5, 2026 - geneonline.com
Three Intellia fireside chats will stream live through June 3 - Stock Titan
Intellia Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
Shareholders of Intellia Therapeutics, Inc. Should Contact Levi - The National Law Review
ARK Invest Increases Stake in Intellia Therapeutics (NTLA) Amid Sector Rotation - GuruFocus
Intellia Therapeutics says its CRISPR-based treatment succeeds in pivotal trial - MSN
Lonvo-z gene-editing therapy lowers HAE attacks by 87% in Phase 3 trial - Angioedema News
Intellia Initiates Rolling BLA Submission For In Vivo CRISPR Therapy In Hereditary Angioedema - marketscreener.com
NTLA stock rises 20% in 3 months: Here's what you should know - MSN
Behavioral Patterns of NTLA and Institutional Flows - Stock Traders Daily
Intellia Therapeutics shares slip despite strong phase 3 data - MSN
symbol__ Stock Quote Price and Forecast - CNN
NTLA jumps premarket on positive late-stage trial data for gene-editing therapy — retail says buy now before it’s too late - MSN
Intellia Therapeutics, Inc. Sued for Securities Law Violations - GuruFocus
Intellia Therapeutics (NTLA) Sees Major Purchase by ARK Investme - GuruFocus
Cathie Wood’s ARK sells AMD stock, buys Roblox and Intellia - Investing.com
Intellia Therapeutics Prices Public Equity Offering to Fund Pipeline - The Globe and Mail
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
43 new Intellia employees get stock awards worth 208,850 shares - Stock Titan
Intellia Therapeutics prices $180M stock offering at discount - MSN
Intellia Therapeutics | DEF 14A: Definitive information statements - Moomoo
Intellia Therapeutics (NTLA) Is Down 15.1% After Phase 3 lonvo-z Data And $180M Equity RaiseHas The Bull Case Changed? - Yahoo Finance
Intellia Therapeutics | SCHEDULE 13G: Others - Moomoo
Intellia (NASDAQ: NTLA) equity sale boosts cash runway into 2028 - Stock Titan
Intellia Therapeutics (NASDAQ: NTLA) sets 2026 virtual meeting on directors, pay and auditor - Stock Titan
MSN Money - MSN
NTLA Stock Draws Bulls After Phase 3 Gene-Editing Win - StocksToTrade
[ARS] Intellia Therapeutics, Inc. SEC Filing - Stock Titan
Vanguard (NTLA) files Schedule 13G reporting 5.03% ownership (5.95M) - Stock Titan
Intellia Therapeutics | 424B5: Prospectus - Moomoo
NTLA Forecast, Price Target & Analyst Ratings | INTELLIA THERAPEUTICS INC (NASDAQ:NTLA) - ChartMill
ARK Investment Acquires 2.4 Million Shares of Intellia Therapeutics (NTLA) - GuruFocus
$Intellia Therapeutics (NTLA.US)$ Hope u will give me good profit starr from today - Moomoo
Intellia Therapeutics (NASDAQ: NTLA) offers 16.7M shares at $10.75 - Stock Titan
NTLA Stock Slides As $150M Offering Signals Dilution Risk - timothysykes.com
Vanguard Portfolio Management holds 5.3% of Intellia (NASDAQ: NTLA) - Stock Titan
CRISPR Breakthrough Brings First In-Body Cure With Lonvo-Z - Forbes
Intellia Therapeutics earnings in focus after gene editing breakthrough By Investing.com - Investing.com South Africa
Intellia Therapeutics earnings in focus after gene editing breakthrough - Investing.com UK
NTLA Stock Pressured As $150M Offering Tests Trader Nerves - StocksToTrade
NTLA Secures $180 Million in Increased Common Stock Offering - GuruFocus
Intellia Therapeutics (NTLA) Launches $180M Public Offering Amid Share Price Drop - GuruFocus
Intellia Therapeutics stock tumbles on discounted offering - Investing.com
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Intellia Therapeutics (NTLA) and Incyte (INCY) - The Globe and Mail
NTLA Stock Slips As $150M Equity Offering Raises Dilution Fears - timothysykes.com
Intellia Files BLA After Lonvo-z Meets Phase 3 Endpoints - CRISPR Medicine News
Intellia Therapeutics stock tumbles on discounted offering By Investing.com - Investing.com India
Intellia Therapeutics stock tumbles on dilutive offering By Investing.com - Investing.com Canada
Intellia Therapeutics stock tumbles on dilutive offering - Investing.com
Finanzdaten der Intellia Therapeutics Inc-Aktie (NTLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Intellia Therapeutics Inc-Aktie (NTLA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Clark Eliana | EVP, Chief Technical Officer |
Mar 02 '26 |
Sale |
13.78 |
607 |
8,364 |
93,864 |
| LEONARD JOHN M | President and CEO |
Jan 05 '26 |
Sale |
9.21 |
34,146 |
314,485 |
1,013,339 |
| Schultes Birgit C | EVP, Chief Scientific Officer |
Jan 05 '26 |
Sale |
9.21 |
8,508 |
78,359 |
98,533 |
| BASTA JAMES | EVP, General Counsel |
Jan 05 '26 |
Sale |
9.21 |
10,397 |
95,756 |
101,528 |
| Cohen Fred E | Director |
Jan 05 '26 |
Buy |
9.35 |
150,000 |
1,402,500 |
207,453 |
| Lebwohl David | EVP, Chief Medical Officer |
Jan 05 '26 |
Sale |
9.21 |
11,903 |
109,627 |
121,249 |
| Clark Eliana | EVP, Chief Technical Officer |
Jan 05 '26 |
Sale |
9.21 |
9,515 |
87,633 |
87,118 |
| Dulac Edward J III | EVP, Chief Financial Officer |
Jan 05 '26 |
Sale |
9.21 |
6,379 |
58,751 |
99,683 |
| Dube Michael P | VP, Chief Accounting Officer |
Jan 05 '26 |
Sale |
9.21 |
2,989 |
27,529 |
52,277 |
| LEONARD JOHN M | President and CEO |
Dec 11 '25 |
Option Exercise |
6.83 |
49,959 |
341,220 |
1,127,074 |
0.78%
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):